Health ❯ Healthcare ❯ Cancer Treatment ❯ Targeted Therapy

EGFR Inhibitors

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

The peer-reviewed FLAURA2 results released at ESMO with NEJM publication now guide first-line care decisions.

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort